Havik 2012.

Study characteristics
Study design	Cohort
Study setting	Setting: Department of Neurosurgery, Oslo University Hospital Country: Norway Dates: surgery between January 2005 and January 2009
Selection of participants	Tumour samples from 134 people with glioma (diffuse astrocytoma WHO grade II (n = 10), oligodendroglioma WHO grade II (n = 6), oligoastrocytoma WHO grade II (n = 17), low‐grade neuroepithelial tumour not otherwise specified (n = 2), anaplastic astrocytoma WHO grade III (n = 4), anaplastic oligodendroglioma, WHO grade III (n = 6), anaplastic oligoastrocytoma WHO grade III (n = 3), GBM WHO grade IV (n = 86)) and 4 people with meningioma
Participant characteristics	Sample size: 134 (deaths: NR) Age: mean 58.5, SD 9.1 years Sex: 53.5% men KPS: NR
Tumour characteristics	GBM: 64.2% First diagnosis: NR Biopsy: NR; subtotal resection: NR; total resection: NR IDH1 wild‐type: NR; IDH2 wild‐type: NR
Treatment regimen	Standard radiotherapy and concomitant TMZ, some also adjuvant TMZ
MGMT promoter methylation tests implemented	MSP, PSQ, qMSP, PCR‐HRM
Dates and follow‐up	Timing of MGMT assessment: not explicitly reported, but presumably on freshly frozen tumour samples obtained during resection/biopsy. Start time for follow‐up: date of first surgery; follow‐up: median NR; range NR
Notes